KMTS Stock Forecast & Price Target

Kestra Medical Technologies Ltd is positioned for significant financial improvement as it anticipates gross margins to reach approximately 70% in the coming fiscal years, driven by enhancements in prescription fulfillment rates and revenue cycle management. The company’s conversion rate, which measures the effectiveness of prescription fulfillment, billing, and payment collection, has seen notable growth from 37.1% in FY24 to 46.8% in the latest quarter, indicating a positive trend in operational efficiency. Additionally, the company's rental model is expected to leverage volume, further contributing to higher gross margins in future years, supported by an increase in ASSURE prescriptions both year-over-year and sequentially.

Kestra Medical Technologies Ltd is experiencing a significant decline in device adherence and wear time for its Cardiac Recovery System platform, as evidenced by the VEST study that reported adherence dropping from 80.8% to 41.3% over 90 days. The company's operating expenses are projected to exceed revenue significantly, with an expected operating expense ratio of 186% of revenue for the fiscal year and projected continued high spending into FY2028, raising concerns about financial sustainability. Furthermore, the slowing growth rate of wearable cardioverter defibrillator adoption at approximately 6% CAGR in the U.S. raises additional doubts about the company’s ability to maintain a competitive advantage in the market.